Operating profit increased by 20% YoY... efforts to strengthen its operations
[by Ji, Yong Jun] Huons announced on May 2 that its preliminary earnings for the first quarter of this year were reported as consolidated sales of 145.8 billion KRW, operating profit of 12.8 billion KRW, and net profit of 12.4 billion KRW, reflecting year-on-year changes of -1.3%, +20.1%, and +26.4%, respectively.
Huons reported solid 메이저 바카라 사이트 with a significantly improved operating margin of 8.8% on consolidated financial statements and 9.8% on separate financial statements. The company achieved the highest operating profit and operating margin in five consecutive quarters from the first quarter of 2024 to the present.
Huons' improved profitability in the first quarter is attributed to the performances of its subsidiaries and company-wide cost control efforts. Huons Foodience (now Huons N), a subsidiary specialized in health functional food business, turned profitable in the first quarter, while HuonsLifeSciences, specialized in ethical drug (ETC), narrowed its deficit, contributing to the improvement in Huons' consolidated net profit.
In addition, by managing and reducing major expenses on advertising and commissions, the SG&A (Selling General & Administrative Expenses) ratio decreased by 3.7%, from 43.2% in the previous year to 39.5%. Among all expenses, research and development expense, the company's key growth engine, continued to increase and be invested in.
By business segment, 메이저 바카라 사이트 growth was led by ETC and diabetes medical devices. In ETC, domestic 메이저 바카라 사이트 related to chronic diseases such as circulatory and metabolic diseases showed steady growth, and antibiotic prescriptions increased due to the flu epidemic at the beginning of the year. The company recorded 4.2 billion KRW (+19% YoY, +37% QoQ) on exports of injectable products to the US, while exports of eye drops to Saudi Arabia, Jordan, and other countries had also contributed to the growth of pharmaceutical 메이저 바카라 사이트.
The company recorded 메이저 바카라 사이트 of 19.1 billion KRW (-2.1% YoY) on contract manufacturing organization (CMO) business. The 메이저 바카라 사이트 for eye drops, including exports and CMO, recorded 12.4 billion KRW, recovered with a 25% increase QoQ. In addition, the operating rate of the new eye drop production line at the second plant, which has been in operation since last year, had increased to 77%.
The beauty and wellness business recorded 메이저 바카라 사이트 of 43.7 billion KRW, decreased by 10.4% YoY. The company commented that the 메이저 바카라 사이트 temporarily declined during the process of the spin-off and merger of its health functional food business into a subsidiary. The company expects to strengthen the ETC business of Huons and the health functional food business of the newly launched company Huons N, leading to enhanced capabilities and expertise in both companies.
Medical device 메이저 바카라 사이트 increased 34.2% year-on-year, driven by Dexcom G7 continuous glucose monitoring system expanding its market share and continuing to grow.
The company accelerates FDA efforts on ANDA generic drug approval for 20ml multi-dose lidocaine and new registration on dental topical anesthetics within the year. In the second half of the year, 메이저 바카라 사이트 are expected to increase as new production lines for injections are put into operation, and profit margins are to further improve as the cost of 메이저 바카라 사이트 recovers.
Huons’ CEO Song Soo-young said, “Completing the merger through spin-off of health functional food business, Huons will further strengthen its unique business areas to increase profitability based on its strong fundamentals. The company plans to expand exports and continue to increase R&D investment for securing visible outcomes and mid- to long-term growth engines, attributed to the new production facilities for injections and eye drops.”